DBV Technologies DBVT
NASDAQ DBVT
$13.53 -0.16 (-1.21%)
As of: Sep 4, 2026 · 12:29 PM EDT

DBV Technologies (DBVT) Net Income towards Common Stockholders (2020 - 2026)

DBV Technologies (DBVT) posted Net Income towards Common Stockholders of -$50.4 million for Q2 2026, down 5.88% sequentially from -$47.6 million in Q1 2026, and down 20.29% YoY from -$63.2 million in Q2 2025.

Analysis

DBV Technologies (DBVT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

DBV Technologies has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$50.4 million in Q2 2026.

  • Quarterly Net Income towards Common Stockholders fell 20.29% year-over-year to -$50.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$176.0 million (down 43.72% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
  • Net Income towards Common Stockholders slipped to -$50.4 million in Q2 2026 per DBVT's latest filing, from -$47.6 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$11.2 million in Q4 2023 and troughed at -$50.4 million in Q2 2026.
  • A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 187.02% in 2022, then surged 71.49% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then sank by 105.75% to -$23.0 million in 2024, then sank by 94.78% to -$44.8 million in 2025, then fell by 12.43% to -$50.4 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$50.4 million, -$47.6 million, and -$44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 DBV Technologies 5.87 Bn 5.69 Bn - -50.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -50.40 Mn
Mar 31, 2026 -47.60 Mn
Dec 31, 2025 -44.83 Mn
Sep 30, 2025 -33.16 Mn
Jun 30, 2025 -41.90 Mn
Mar 31, 2025 -27.10 Mn
Dec 31, 2024 -23.02 Mn
Sep 30, 2024 -30.44 Mn
Jun 30, 2024 -33.12 Mn
Mar 31, 2024 -27.35 Mn
Dec 31, 2023 -11.19 Mn
Sep 30, 2023 -16.74 Mn
Jun 30, 2023 -24.24 Mn
Mar 31, 2023 -20.56 Mn
Dec 31, 2022 -39.24 Mn
Sep 30, 2022 -17.29 Mn
Jun 30, 2022 -23.04 Mn
Mar 31, 2022 -16.71 Mn
Dec 31, 2021 -13.67 Mn
Sep 30, 2021 -24.03 Mn